To describe outcomes, treatment and prognostic factors that influence survival of adult patients with acute lymphoblastic leukemia (ALL), who relapsed after allogeneic hematopoietic cell transplantation (HCT), we retrospectively analyzed 465 ALL adult patients from European Group for Blood and Marrow Transplantation (EBMT) centers who relapsed after a first HCT performed in complete remission (CR1 65%, CR2/3 35%). Salvage treatments were: supportive care (13%), cytoreductive therapy (43%), donor lymphocyte infusion without or with prior chemotherapy (23%) and second HCT (20%). Median time from HCT to relapse was 6.9 months, median follow-up was 46 months and median survival after relapse was 5.5 months. Estimated 1-, 2-and 5-year post-relapse survival was 30 ± 2%, 16 ± 2% and 8 ± 1%, respectively. In a multivariate analysis, adverse factors for survival were: late CR (CR2/3) at transplant (Po0.012), early relapse after transplant (o6.9 months, P o0.0001) and peripheral blast percent at relapse (P o0.0001). On the basis of multivariate model for survival, three groups of patients were identified with estimated 2 year survival of 6 ± 2, 17 ± 3 and 30 ± 7%. Outcome of ALL patients relapsing after HCT is dismal and there is a need for new therapies. Our study provides the standard expectations in ALL relapse and may help in the decision of postrelapse therapy.
INTRODUCTION
Recent studies suggesting that not only high risk but also standard risk adult patients suffering from acute lymphoblastic leukemia (ALL) benefit from allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR), resulted in an increasing use of this procedure in the frontline management of adult ALL. 1, 2 Indeed, the last 2008 activity survey of the European Group for Blood and Marrow Transplantation (EBMT) indicated that of a total of 10782 allogeneic transplants, 1860 were done in ALL patients. 3 However, nearly 20 --40% of patients undergoing allo-HCT in first CR will relapse. 1 It is thought that adults with ALL who experience relapse after allo-HCT fair poorly, but there is limited data defining their precise outcome. 4 Common treatments for relapse after allo-HCT include chemotherapy, tyrosine kinase inhibitors in Ph þ ALL, donor lymphocyte infusions (DLI) 5 and second transplantation. 6, 7 Moreover, many times the decision of whether or not to treat patients relapsing after HCT is very difficult, and little is known how these therapeutic interventions are applied across transplant centers and what their value is. We therefore performed a retrospective analysis of patients with relapsed ALL after allo-HCT being transplanted in CR and the strategies adopted by EBMT centers. Besides reporting on applied treatment strategies and outcome, we determined prognostic factors that affect survival and provide guidance concerning which patients are most likely to benefit from post-relapse therapy.
PATIENTS AND METHODS

Data collection and inclusion criteria
EBMT is a voluntary working group of 605 transplant centers. Participating centers are required to report all transplantations consecutively, and the compliance is monitored by on-site audits. For this study, EBMT centers were asked to report their experience in the treatment of ALL relapse after allo-HCT. Inclusion was based on the following criteria: confirmed diagnosis of ALL, age X18 years; first sibling or matched unrelated allo-HCT with peripheral blood stem cells or bone marrow (BM), transplants performed in complete hematological remission between 1995 --2006 and first hematological and/or extramedullary relapse after HCT. Hematological relapse was defined by infiltration of BM by 45% blasts or recurrence of blasts in peripheral blood. Isolated extramedullary relapse has to be proved with biopsy. Patients showing only decreasing donor chimerism or cytogenetic/ molecular relapse were excluded. A specific questionnaire was created to collect data on the relapse and treatment characteristics for the patients. Poor risk cytogenetics included t(9;22) or t(4;11). 8 According to the EBMT definition, reduced intensity conditioning was defined as the use of fludarabine combined with low-dose total body irradiation (o3 Gy) or oral busulfan (total dose o8 mg/kg), or i.v busulfan (6.4 mg/kg) or other nonmyeloablative drugs. 9 Definitions of salvage interventions Salvage treatments were administrated on the basis of centers' preference. Patients were categorized by therapy received after relapse as follows: (a) patients who received only supportive care, (b) patients who received cytoreductive therapy, which includes chemotherapy and/ or radiation of extramedullary relapses and/or tyrosine kinase inhibitor, (c) patients who received therapy aiming at enhancing the graft versus leukemia effect, which includes administration of DLI, defined as previously, 10 and/or cytokines without or with prior administration of any cytoreductive therapy and (d) patients who underwent second transplantations irrespective of whether they had received other kind of salvage treatment before.
Statistical analysis
The primary end point was overall survival (OS) after post-transplantation relapse. For all prognostic analyses, continuous variables were categorized according to the median. Probabilities of OS were evaluated using the Kaplan --Meier method. Associations between pre-transplant characteristics, transplant and relapse characteristics with post-relapse survival were evaluated by comparing OS curves between subgroups using the log-rank test. Factors associated with a Po0.10 by univariate analysis were entered into Cox proportional hazard models for multivariate analysis. A stepwise backward procedure was used to construct a set of independent factors at time of relapse for post-relapse OS. A cutoff significance level of Po0.05 was used for deleting factors. All tests were two sided. Based on the final model, we were able to establish a score according to the number of adverse prognostic factors at the time of relapse. Statistical analyses performed with SPSS software 18.0 (SPSS Software Inc., Chicago, IL, USA).
RESULTS
Patient and disease characteristics at transplantation
A total of 1045 patients identified in the registry met the eligibility criteria. In all, 84 centers (see Appendix) completed the specific questionnaire of 465 adult patients with ALL who were allografted in remission between 1995 and 2006 (median 2002) and who relapsed thereafter ( Table 1 ). The median age at diagnosis was 32 years (18 --66) . Immunophenotype at the time of initial diagnosis was available in 97% (451) patients; 76% (345) had B-lineage, 21% (94) had T-lineage and the remaining 3% (12) had undifferentiated ALL. Among the 80% (373) patients for which cytogenetic and/ or molecular evaluation was available, t (9;22) and/or the BCR-ABL rearrangement was found in 42% (157) and t(4;11)/MLL-AF4 in 3% (13) . In all, 65% (300) patients were transplanted in first CR, 32% (149) in second CR and 3% (16) in third CR. About that 92% (426) of patients received a myeloablative conditioning regimen, which included total body irradiation in 69% (322) of patients. Patients were transplanted from a sibling donor in 68% (316) of the cases and from an unrelated donor in 32% (149). The source of stem cells was peripheral blood stem cells in 53% (246) patients and BM in 47% (218).
Relapse characteristics Median time from transplantation to relapse was 6.9. months (range, 0.8 --57). Most (74%, 345) relapses occurred within 1 year Therapy for relapse In all, 13% (62) relapsed patients received supportive care only. In 43% (202) of the patients treatment of relapse consisted of chemotherapy, and/or radiation to extramedullary sites and/or tyrosine kinase inhibitor (61% of the Ph þ cases, 37 patients) without further infusion of any cells with therapeutic purposes. DLI-based therapies were employed in 23% (108) of the patients and were given in a median of 45 days (range, 4 --344) after relapse. Chemotherapy was given before DLI in 19% (90) patients, whereas 4% (18) relapses were treated with DLI alone without preceding chemotherapy. Second transplants were administered to 20% (93) of the patients within a median of 71 days (7 --286) after relapse. Table 2 shows the distribution of the different salvage interventions according to disease, transplant and relapse characteristics. Patients receiving supportive care only had been transplanted in more advanced stages (CR2/3), had relapsed earlier and revealed more frequently circulating blasts at relapse, reflecting a more aggressive disease.
OS after relapse With a median follow-up of 46 months (1 --117), the median OS after relapse was 5.5 months (Figure 1 ). Although 37% (172) patients could achieve a new remission within a median of 48 days (range 6 --333), the survival rates remained low. The estimated 1-, 2-and 5-year post-relapse survival was 30±s.d. 2%, 16 ± s.d. 2% and 8 ± s.d. 1 %, respectively. Median post-relapse survival was 1.6 months for the patients who received supportive care only, 3.5 months for the patients treated with cytoreductive therapy without any further cellular therapy, 9.8 months for patients treated with DLI and 12.6 months for the patients who received second transplants. Among the 10% (48) patients reported to be alive, 4% (18) had been treated with chemotherapy only (median follow-up 34 months), 5% (24) had received DLI (median follow-up 49 months) and 1% (6) had undergone second transplantation (median follow-up 41 months). The main cause of death was leukemia in 87% (404) of the patients, followed by infection (5%, 23 patients), graft-versus-host-disease (6%, 28 patients) and other causes (2%, 9 patients).
Analyses of risk factors associated with survival after relapse Table 3 shows the univariate analysis of factors associated with 2-year post-relapse survival. Improved survival was associated with transplantation in CR-1, a longer interval from transplantation to relapse (4median 6.9 months), a lower number of BM blasts (omedian 60%) and the absence or lower (omedian 10%) number of circulating blasts at the time of relapse. Age at transplant, disease characteristics (immunophenotype, high risk Ph þ or t 4;11) and transplant characteristics (donor, stem cell source, conditioning intensity and conditioning type) had no significant impact on post-relapse survival. Among the different treatment groups, the estimated 2-year post-relapse survival was 4±s.d. 3% for the patients who received supportive care only, 9 ± s.d. 2% for the patients treated with cytoreductive therapy without any further cellular therapy, 26 ± s.d. 5% for the patients who received chemotherapy followed by DLI, 18±s.d. 9% for the patients treated with DLI only and 26±s.d. 5% for the patients who underwent a second transplantation. Unfortunately, the different characteristics among patients of the different treatment groups, as well as the retrospective nature of the study preclude comparisons by treatment groups.
In a multivariate analysis (Table 4) , transplantation performed in CR2/CR3, early relapse (o6.9 months) and the presence of 410% blasts in peripheral blood at the time of relapse proved to be independent adverse factors of post-relapse survival. The number of BM blasts was closely linked to the number of circulating blasts and was therefore eliminated from the model. Based on this multivariate model, we could define three prognostic groups. Patients with three adverse factors, who compromised 42% (195) of the study, had the worse prognosis with a median post-relapse survival of 3.05 months and a 2-year OS of 6±s.d. 2%. Patients with two adverse factors had a median survival of 6.6 months and an estimated 2-year post-relapse survival of 17 ± s.d. 3%, whereas median survival and 2 years OS in the remaining 15% (70) patients with zero or only one adverse factor was 10.5 months and 30±s.d. 7%, respectively (Figure 2) .
DISCUSSION
This retrospective, registry-based analysis is the first large study that has focused on the outcome of adult ALL patients who experience relapse after allo-HCT. We were able to analyze 465 patients out of 1045 who relapsed after an allogeneic HCT. Our first concern was regarding the reproducibility of the results among patients with and without available detailed information on the treatment for relapse. In fact, estimated 2 year survival was 16% ± 2 for those patients with information (n ¼ 465) compared with 18%±2 for 580 patients without sufficient information (P ¼ ns) (data not shown). Most relevant data on recurring ALL rely on patients who relapsed after conventional therapy (French LALA-94, 11 British Medical Research Counsil UKALL12/ ECOG2993, 12 Spanish PETHEMA, 13 MD Anderson Cancer Center 14 trials). Here, we define the outcome and the prognostic factors that influence survival of ALL patients who were consolidated with allo-HCT and subsequently relapsed. This information on standard expectations in ALL relapse after allo-HCT is important for patients, advising clinicians and those involved in the design of investigational salvage treatments. Our study emphasizes the dismal prognosis of ALL patients once they relapsed after transplantation. Estimated 5-year survival of 8% and median survival of 5.5 months highlight the need for new therapeutic strategies. It can be assumed that relapsed ALL after transplantation has more aggressive course than relapsed ALL after conventional chemotherapy owing to the persistence of a more resistant clone(s). 15 Yet, survival curves of patients who experience relapse after conventional chemotherapy are similar, with a median survival ranging between 4.5 --6 months and 5-year survival of 7 --12%. The multivariate analysis in the British, 12 Spanish 13 and French 11 ALL trials demonstrated that relapsed patients had the same outcome whether or not they received chemotherapy or transplantation as part of their initial therapy. These results are most probably explained by the particularly poor outcome of all recurring ALL, irrespective of their initial treatment. In our current analysis, which was focused on transplanted patients only, we also found that type of transplantation (i.e., donor type, stem cell source, conditioning intensity and type) did not affect outcome after relapse. Obviously, as our analysis has included relapsed patients only, our data cannot contribute to the debate about which is the best conditioning regimen 16 or graft source 17 for ALL patients. However, they reinforce the fact that prevention of leukemia relapse, sometimes at the expense of a higher risk of transplantation-related mortality, should be the major goal when designing transplantation studies in ALL.
The prognosis of patients relapsing after allo-HCT seems to be determined mainly by relapse characteristics. Prognostic factors that were associated independently with poor survival were early relapse, number of bone marrow and circulating blasts at relapse and advanced disease at transplantation greater than CR1). All these factors probably define a biologically more aggressive type of relapse. In contrast to recurring ALL after conventional chemotherapy, we did not find age to influence prognosis of post-transplant relapse. This finding might be partially explained by the fact that in contrast to published multicenter national trials, 11 --13 our patient cohort did not include young adolescents 15 --18 years of age (in which disease is biologically distinct than in adults 18 ) as well as older patients ineligible for a transplant procedure. As in studies of relapsed ALL after conventional chemotherapy, we failed to identify any influence of immunophenotype and cytogenetic risk stratification at diagnosis on prognosis after relapse. However, in the case of Ph þ ALL, it cannot be excluded that a positive influence of TKI inhibitors on survival may have decreased a possible negative prognostic relevance of the high-risk karyotype in the outcome after relapse. During the study period, imatinib was the standard available TKI inhibitor, and therefore, no conclusion can be made about the impact of the new, more potent TKIs available nowadays.
What is the best salvage treatment for these patients is not known. 19 The nature of this retrospective analysis and the bias in the treatment selection did not allow comparisons between treatment groups within our study, and precludes any statement regarding the best salvage intervention. Contrary to the current belief that graft versus leukemia-based therapies are ineffective in ALL, 5 23% and 20% of the patients received DLIs and second allo-HCT, respectively, and these therapies seemed to be the most effective with median survival of 9.8 months and 12.6 months after DLI and second allo-HCT, respectively, as compared with chemotherapy alone (median 3.5 months). However, these differences do not achieve statistical significance and are probably biased by the fact that patients receiving cell-based therapies were more likely positively selected, including those who achieved previous remission and those who lived long enough to organize donor procurement. Second allo-HCT, though less successful than in relapsed AML, is thought to be a curative option. 6, 7, 20 Unfortunately, among the 93 patients who underwent second transplantation, only 6 remained alive at the last control, raising the question whether stem cell donations (especially from unrelated donors) are justified in this situation. 21 Second transplantations in relapsed ALL should optimally be performed within clinical trials specifically designed for these patients. The use of rapidly available stem cell sources, such as cord blood and haploidentical donors should be further investigated.
Although our results are based on retrospective data, they provide important prognostic information and may aid in treatment decisions. On the basis of multivariate model for survival, we identified three groups of patients whether they have three, two or zero/one adverse factors. Adverse factors were transplantation at late CR (CR2/3), early relapse (o6.9 months) and peripheral blast percent at relapse (410%). Obviously, the prognostic model derived from our registry data needs validation in prospective studies and the treatment decision should be made on an individual basis. Nevertheless, the prognostic score could provide guidance to the physician for a more thorough understanding of the risk profile and a more precise advice to the patient by delineating patients in whom a small but important chance to benefit from post-relapse therapy exists from those in whom there is a very little realistic opportunity for long-term survival. As patients with three adverse factors did so poorly with currently available therapies, exploration of novel and alternative approaches or palliation only seems to be justified for these patients. A number of new drugs with different mechanisms of action as well as innovative cellular therapies are being currently investigated in clinical trials (reviewed in van den Brink et al 19 ; Pui and Jeha 22 ; Lee-Sherick 23 ). Patients with none or one adverse factor are most likely the ones who exhibited a sensitive leukemia clone, which may translate into long-term survival. Hence, these patients should be offered the maximum therapy available. As allo-HCT is regarded as the only potentially curative therapeutic option in relapsed patients, probably the best strategy for these patients will be to treat them within a prospective clinical trial involving second transplantation. Nevertheless, as long as prospective data are not available, the wishes of patients and their families, performance status, comorbidities and other less well-quantifiable social factors are important determinants in the therapeutic decision making.
Three major issues are highlighted through this study. First, as most relapsed patients cannot be rescued using currently available therapies, it is crucial to establish and evaluate in prospective studies strategies to prevent relapse. Interesting approaches include the use of prophylactic DLI, 24 residual disease-triggered DLI administration, 26 the adoptive transfer of engineered cytotoxic T lymphocytes, 27, 28 and the maintenance therapy with TKI 29 or monoclonal antibodies directed against antigens expressed by leukemic cells (anti-CD20/22/33). 30 Second, though we were able to identify clinical correlates of the relapse biology and prognosis (such as duration of CR and number of circulating blasts), a better understanding of the molecular abnormalities responsible for relapse may point to new targets for therapeutic intervention. 15 Third, there is an urgent need for more effective therapies for relapsed ALL. Current novel approaches include new antimetabolites and nucleoside analogs, 31, 32 new monoclonal antibodies, new inhibitors of oncogenic kinases, farnesyl transferase and heat-shock protein inhibitors, and agents that target pathways of resistance (for example, anti-bcl-2). 22, 23 Our study provides the baseline against which the efficacy of these new approaches can be compared.
